# Dostarlimab

Dostarlimab (Jemperli, GlaxoSmithKline Trading Services Limited) has 2 EU-approved indications in 1 tumour type. 1 needs a biomarker result: MMR/MSI (1).

## Approved indications

### Endometrial cancer

| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| None | + carboplatin and paclitaxel | 1st line, advanced | Candidates for systemic therapy |
| MMR/MSI deficient | Monotherapy | 2nd line, advanced | Progressed on or following prior treatment with a platinum-containing regimen |

## Products

### Jemperli

- Company: GlaxoSmithKline Trading Services Limited
- Target: PD-1 inhibitor (antibody)
- Class: PD-1/PD-L1 (programmed cell death protein 1/death ligand 1) inhibitors
- ATC: L01FF07
- EU approval: 21 Apr 2021
- Label revised: 13 Oct 2026
- SmPC (EN): https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf
- Fachinformation (DE): https://www.ema.europa.eu/de/documents/product-information/jemperli-epar-product-information_de.pdf
- EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli

Mechanism (SmPC section 5.1): Dostarlimab binds to PD-1 receptors and blocks interaction with PD-L1 and PD-L2, reactivating and potentiating anti-tumour T-cell responses.

## Label wording

- **Dostarlimab** (Jemperli), Endometrial cancer, 1st line, advanced: “JEMPERLI is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf)
- **Dostarlimab** (Jemperli), Endometrial cancer, 2nd line, advanced: “JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/drugs/dostarlimab